[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531694":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":40,"locations":50,"responsibleParty":302,"collaborators":304,"id":310,"slug":311,"hasResults":312,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":312,"sex":318,"minAge":319,"maxAge":31,"enrollmentInfo":320,"targetDuration":31,"studyType":323,"phases":324,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":53,"whyStopped":31,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":344},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Doravirine arm","EXPERIMENTAL","Doravirine (100 mg) + tenofovir DF (300 mg) + lamivudine (300mg) administered daily",[13],"Drug: Doravirine + tenofovir DF + lamivudine",{"label":15,"type":16,"description":17,"interventionNames":18},"Dolutegravir arm","ACTIVE_COMPARATOR","Dolutegravir (50 mg) + tenofovir DF 300 mg + XTC (300 mg if lamivudine or 200 mg if emtricitabine) administered daily",[19],"Drug: Dolutegravir + tenofovir DF + lamivudine or emtricitabine",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Doravirine + tenofovir DF + lamivudine","Oral administration",[9],[27],"Delstrigo",{"type":22,"name":29,"description":24,"armGroupLabels":30,"otherNames":31},"Dolutegravir + tenofovir DF + lamivudine or emtricitabine",[15],null,[33,37],{"name":34,"affiliation":35,"role":36},"Pierre SELLIER, Dr","Assistance Publique - Hôpitaux de Paris","PRINCIPAL_INVESTIGATOR",{"name":38,"affiliation":39,"role":36},"Beatriz GRINSZTEJN, Pr","INI-FIOCRUZ",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Anthony L'HOSTELLIER","CONTACT","33 (0)5 57 57 47 11","anthony.lhostellier@u-bordeaux.fr",{"name":47,"role":43,"phone":48,"phoneExt":31,"email":49},"Olivier MARCY, Dr","33 (0)5 57 57 13 93","olivier.marcy@u-bordeaux.fr",[51,70,83,98,113,123,133,149,159,173,187,200,210,221,232,243,258,274,288],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Hospital Geral de Nova Iguaçu","RECRUITING","Nova Iguaçu","Rio de Janeiro","26030-380","Brazil","BR",{"type":60,"coordinates":61},"Point",[62,63],-43.45111,-22.75917,{"lat":63,"lon":62},[66],{"name":67,"role":43,"phone":68,"phoneExt":31,"email":69},"Luis Eduardo FERNANDES, Dr","+55 21 997938393","luisebcf@gmail.com",{"facility":71,"status":53,"city":55,"state":55,"zip":72,"country":57,"countryCode":58,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Laboratory on Clinical research on AIDS-INI FIOCRUZ","21040-900",{"type":60,"coordinates":74},[75,76],-43.18223,-22.90642,{"lat":76,"lon":75},[79],{"name":80,"role":43,"phone":81,"phoneExt":31,"email":82},"Sandra WAGNER CARDOSO, Dr","+55 21 38 65 96 23","sandra.wagner@ini.fiocruz.br",{"facility":84,"status":53,"city":85,"state":31,"zip":31,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Hôpital Central de Yaoundé","Yaoundé","Cameroon","CM",{"type":60,"coordinates":89},[90,91],11.51667,3.86667,{"lat":91,"lon":90},[94],{"name":95,"role":43,"phone":96,"phoneExt":31,"email":97},"Charles KOUANFACK, Pr","+237 699 95 07 43","charleskouanfack@yahoo.fr",{"facility":99,"status":100,"city":101,"state":31,"zip":31,"country":102,"countryCode":31,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Centre de prise en charge de Recherche et de Formation (CEPREF)","NOT_YET_RECRUITING","Abidjan","Côte d’Ivoire",{"type":60,"coordinates":104},[105,106],-4.00167,5.35444,{"lat":106,"lon":105},[109],{"name":110,"role":43,"phone":111,"phoneExt":31,"email":112},"Amani ANZIAN, Dr","+225 0140185774","amani_anzian@yahoo.fr",{"facility":114,"status":100,"city":101,"state":31,"zip":31,"country":102,"countryCode":31,"cosmosGeoPoint":115,"geoPoint":117,"contacts":118},"Centre Médical de Suivi des Donneurs de Sang (CMSDS) - Centre National de Transfusion Sanguine (CNTS)",{"type":60,"coordinates":116},[105,106],{"lat":106,"lon":105},[119],{"name":120,"role":43,"phone":121,"phoneExt":31,"email":122},"Albert KLA MINGA, Dr","+225 0140732382","minga.kalbert@gmail.com",{"facility":124,"status":53,"city":101,"state":31,"zip":31,"country":102,"countryCode":31,"cosmosGeoPoint":125,"geoPoint":127,"contacts":128},"CHU de Treichville, Service des Maladies Infectieuses et Tropicales (SMIT)",{"type":60,"coordinates":126},[105,106],{"lat":106,"lon":105},[129],{"name":130,"role":43,"phone":131,"phoneExt":31,"email":132},"Serge EHOLIE, Pr","+2250708641080","sergeholie@yahoo.fr",{"facility":134,"status":53,"city":135,"state":31,"zip":136,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"CHU Bordeaux Pellegrin - Service des Maladies Infectieuses et Tropicales","Bordeaux","33075","France","FR",{"type":60,"coordinates":140},[141,142],-0.58046,44.84124,{"lat":142,"lon":141},[145],{"name":146,"role":43,"phone":147,"phoneExt":31,"email":148},"Charles CAZANAVE, Pr","+33 (0)5 56 79 55 36","charles.cazanave@chu-bordeaux.fr",{"facility":150,"status":53,"city":135,"state":31,"zip":136,"country":137,"countryCode":138,"cosmosGeoPoint":151,"geoPoint":153,"contacts":154},"CHU Bordeaux St André - Service de Médecine Interne",{"type":60,"coordinates":152},[141,142],{"lat":142,"lon":141},[155],{"name":156,"role":43,"phone":157,"phoneExt":31,"email":158},"Fabrice BONNET, Pr","+33 (0)5 56 79 57 33","fabrice.bonnet@chu-bordeaux.fr",{"facility":160,"status":53,"city":161,"state":31,"zip":162,"country":137,"countryCode":138,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"CHU Montpellier - Hôpital La Colombière - Service des Maladies Infectieuses et Tropicales","Montpellier","34295",{"type":60,"coordinates":164},[165,166],3.87635,43.61093,{"lat":166,"lon":165},[169],{"name":170,"role":43,"phone":171,"phoneExt":31,"email":172},"Alain MAKINSON, Pr","+33 (0)4 67 33 95 10","a-makinson@chu-montpellier.fr",{"facility":174,"status":53,"city":175,"state":31,"zip":176,"country":137,"countryCode":138,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"CHU Nantes Hôtel Dieu - Service des Maladies infectieuses et tropicales","Nantes","44093",{"type":60,"coordinates":178},[179,180],-1.55336,47.21725,{"lat":180,"lon":179},[183],{"name":184,"role":43,"phone":185,"phoneExt":31,"email":186},"Colin DESCHANVRES, Dr","+33 (0)2 40 08 31 10","colin.deschanvres@chu-nantes.fr",{"facility":188,"status":53,"city":189,"state":31,"zip":190,"country":137,"countryCode":138,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"AP-HP Hôpital Lariboisière - Service de Maladies Infectieuses et Tropicales","Paris","75010",{"type":60,"coordinates":192},[193,194],2.3488,48.85341,{"lat":194,"lon":193},[197],{"name":34,"role":43,"phone":198,"phoneExt":31,"email":199},"+33 (0)1 49 95 80 37","pierre.sellier@aphp.fr",{"facility":201,"status":53,"city":189,"state":31,"zip":190,"country":137,"countryCode":138,"cosmosGeoPoint":202,"geoPoint":204,"contacts":205},"AP-HP Hôpital Saint Louis - Service des Maladies Infectieuses et Tropicales",{"type":60,"coordinates":203},[193,194],{"lat":194,"lon":193},[206],{"name":207,"role":43,"phone":208,"phoneExt":31,"email":209},"Nathalie DE CASTRO, Dr","+33 (0)1 42 49 45 72","nathalie.de-castro@aphp.fr",{"facility":211,"status":53,"city":189,"state":31,"zip":212,"country":137,"countryCode":138,"cosmosGeoPoint":213,"geoPoint":215,"contacts":216},"AP-HP Hôpital Saint Antoine - Service des Maladies Infectieuses et Tropicales","75012",{"type":60,"coordinates":214},[193,194],{"lat":194,"lon":193},[217],{"name":218,"role":43,"phone":219,"phoneExt":31,"email":220},"Karine LACOMBE, Pr","+33 (0)1 49 28 31 96","karine.lacombe2@aphp.fr",{"facility":222,"status":53,"city":189,"state":31,"zip":223,"country":137,"countryCode":138,"cosmosGeoPoint":224,"geoPoint":226,"contacts":227},"AP-HP Hôpital Pitié Salpêtrière - Service des Maladies Infectieuses et Tropicales","75013",{"type":60,"coordinates":225},[193,194],{"lat":194,"lon":193},[228],{"name":229,"role":43,"phone":230,"phoneExt":31,"email":231},"Valérie POURCHER, Pr","+33 (0)1 42 16 01 01","valerie.martinez@aphp.fr",{"facility":233,"status":53,"city":189,"state":31,"zip":234,"country":137,"countryCode":138,"cosmosGeoPoint":235,"geoPoint":237,"contacts":238},"AP-HP Bichat Claude Bernard - Service des Maladies Infectieuses et Tropicales","75018",{"type":60,"coordinates":236},[193,194],{"lat":194,"lon":193},[239],{"name":240,"role":43,"phone":241,"phoneExt":31,"email":242},"Jade GHOSN, Pr","+33 (0)1 40 25 78 03","jade.ghosn@aphp.fr",{"facility":244,"status":53,"city":245,"state":31,"zip":31,"country":246,"countryCode":247,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"Centro de Saúde 1o de Maio","Maputo","Mozambique","MZ",{"type":60,"coordinates":249},[250,251],32.58322,-25.96553,{"lat":251,"lon":250},[254],{"name":255,"role":43,"phone":256,"phoneExt":31,"email":257},"Neiva BANZE, Dr","+ 258 84 053 3250","neiva.banze@ins.gov.mz",{"facility":259,"status":100,"city":260,"state":31,"zip":261,"country":262,"countryCode":263,"cosmosGeoPoint":264,"geoPoint":268,"contacts":269},"Chiangrai Prachanukroh","Chiang Rai","57000","Thailand","TH",{"type":60,"coordinates":265},[266,267],99.8325,19.90858,{"lat":267,"lon":266},[270],{"name":271,"role":43,"phone":272,"phoneExt":31,"email":273},"Suwimon KHUSUWAN, Dr","+66 814865047","ngornaja@yahoo.com",{"facility":275,"status":100,"city":276,"state":31,"zip":277,"country":262,"countryCode":263,"cosmosGeoPoint":278,"geoPoint":282,"contacts":283},"Lampang Hospital Internal Medicine department","Lampang","52000",{"type":60,"coordinates":279},[280,281],99.49277,18.29232,{"lat":281,"lon":280},[284],{"name":285,"role":43,"phone":286,"phoneExt":31,"email":287},"Parichart SAKULKONKIJ, Dr","+66815958662","parichart1507@gmail.com",{"facility":289,"status":100,"city":290,"state":31,"zip":291,"country":262,"countryCode":263,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"Phayao Hospital Internal Medicine department","Phayao","56000",{"type":60,"coordinates":293},[294,295],99.87883,19.19203,{"lat":295,"lon":294},[298],{"name":299,"role":43,"phone":300,"phoneExt":31,"email":301},"Guttiga HALUE, Dr","+6689933568","drgutti@gmail.com",{"type":303,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[305,308],{"name":306,"class":307},"MSD France","INDUSTRY",{"name":309,"class":6},"European and Developing Countries Clinical Trials Partnership (EDCTP)","100531694","phase-3-doravirine-versus-dolutegravir-based-antiretroviral-regimens-in-treatment-nave-people-living-with-hiv-1-infection-100531694",false,"NCT06203132","DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","Phase III, Open-label, Randomized, Multicenter Trial EvaLuating the Non-inferiority of DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","ELDORADO","Inclusion Criteria:\n\n* Be at least 18 years of age on the day of signing the informed consent.\n* Be HIV-1 positive as determined according to national testing strategies\n* Have a plasma HIV-1 RNA ≥1000 copies\u002FmL within 30 days prior to the randomization,\n* Have HIV treatment indication based on physician assessment according to local treatment guidelines\n* Be naïve to antiretroviral therapy (ART) including investigational antiretroviral agents\n* For women or transgender men of childbearing potential i.e. of childbearing age who are not menopausal, or permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or not refraining from sexual activity: negative urinary test for pregnancy and acceptance to use contraceptive methods\n* Understand the study procedures and voluntarily agree to participate by giving written informed consent for the trial.\n\nNon-inclusion Criteria:\n\n* Has ongoing (pulmonary or extra-pulmonary) tuberculosis\n* Has any other history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.\n* Is infected with HIV-2 or co-infected with HIV-1 and HIV-2\n* Has received cabotegravir long acting or dapivirine pre-exposure prophylaxis (PrEP).\n* Has received oral pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) in the past three months or has had no negative HIV-1 serology performed\n* Has documented or known resistance or possible resistance to study drugs (in France and where national guidelines recommend screening for primary resistance before starting first-line ART) as defined by the ANRS MIE AC43 Resistance group\n* Has the following laboratory values at screening visit, within 30 days prior to the randomization:\n\n  * AST (SGOT) and ALT (SGPT) \\>4.0 x upper limit of normal\n  * Estimated glomerular filtration rate at time of screening \\\u003C60 mL\u002Fmin\u002F1.73m², based on the CKD-EPI equation\n* Has participated in a study with an investigational compound\u002Fdevice within 30 days prior to signing informed consent or anticipates participating in such a study involving an investigational compound\u002Fdevice during the course of this study.\n* Has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study\n* Requires or is anticipated to require any of the prohibited or contraindicated medications noted in the trial protocol.\n* Has significant hypersensitivity or other contraindication to any of the components of the study drugs.\n* Is pregnant, breastfeeding, or expecting to conceive at any time during the study.\n* Has any condition which might, in the investigator's opinion, compromise the safety of treatment and\u002For patient's adherence to study procedure.\n* Is a person under guardianship or deprived of freedom by a judicial or administrative decision","ALL","18 Years",{"count":321,"type":322},610,"ESTIMATED","INTERVENTIONAL",[325],"PHASE3","Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.",[328],"HIV-1-infection",[330,331,332,333,334],"HIV-1","ART-naïve","doravirine","dolutegravir","non-inferiority","2026-01-06",{"date":337,"type":338},"2026-01-07","ACTUAL",{"date":340,"type":338},"2025-01-27",{"date":342,"type":322},"2027-11",{"name":5,"class":6},19]